[{"orgOrder":0,"company":"Shanghai Pharma Group","sponsor":"ImmVira","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Microorganism","year":"2020","type":"Collaboration","leadProduct":"T3011","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Pharma Group","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Intratumoral Injection","sponsorNew":"Shanghai Pharma Group \/ Shanghai Pharma Group","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Pharma Group \/ Shanghai Pharma Group"},{"orgOrder":0,"company":"Shanghai Pharma Group","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Eravacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shanghai Pharma Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Pharma Group \/ Everest Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Shanghai Pharma Group \/ Everest Medicines"}]

Find Clinical Drug Pipeline Developments & Deals by Shanghai Pharma Group

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Under the partnership, Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA (eravacycline), a novel, fully synthetic, fluorocycline intravenous antibiotic, in China.

                          Product Name : Xerava

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 18, 2023

                          Lead Product(s) : Eravacycline

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Everest Medicines

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : The license agreement is focused on ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors.

                          Product Name : Undisclosed

                          Product Type : Microorganism

                          Upfront Cash : Undisclosed

                          June 08, 2020

                          Lead Product(s) : T3011

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : ImmVira

                          Deal Size : $170.0 million

                          Deal Type : Collaboration

                          blank